Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-03 07:00 |
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Inve…
|
English | 106.2 KB | ||
| 2025-02-28 17:45 |
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for…
|
English | 245.3 KB | ||
| 2025-02-28 17:45 |
Valneva reçoit un avis positif du CHMP de l’EMA pour élargir l’indication de so…
|
French | 231.5 KB | ||
| 2025-02-18 07:00 |
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 O…
|
English | 224.9 KB | ||
| 2025-02-18 07:00 |
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exerc…
|
French | 214.6 KB | ||
| 2025-02-06 18:00 |
Déclaration d'actions et de droits de vote de la société Valneva SE - Janvier 2…
|
French | 156.2 KB | ||
| 2025-02-06 18:00 |
Shareholding declaration Valneva SE - January 2025
|
English | 97.2 KB | ||
| 2025-02-05 07:00 |
Valneva reçoit une autorisation de mise sur le marché au Royaume-Uni pour le pr…
|
French | 230.9 KB | ||
| 2025-02-05 07:00 |
Valneva Receives Marketing Authorization in the UK for the World’s First Chikun…
|
English | 249.0 KB | ||
| 2025-01-30 17:45 |
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a …
|
English | 127.8 KB | ||
| 2025-01-30 17:45 |
Valneva annonce un nouveau contrat d’une valeur minimale de $32.8 millions avec…
|
French | 150.8 KB | ||
| 2025-01-22 17:45 |
Valneva annonce des résultats de Phase 2 positifs chez les enfants pour son vac…
|
French | 248.1 KB | ||
| 2025-01-22 17:45 |
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccin…
|
English | 231.9 KB | ||
| 2025-01-20 17:45 |
Valneva annonce une réponse immunitaire robuste et durable chez les adolescents…
|
French | 227.0 KB | ||
| 2025-01-20 17:45 |
Valneva Reports High Sustained Immune Response in Adolescents One Year After Si…
|
English | 188.0 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
